Ilaris

Canakinumab, the active ingredient in Ilaris, is a interleukin-1 beta inhibitor presented as a solution for subcutaneous injection for subcutaneous use. It treats autoinflammatory disorders such as cryopyrin‑associated periodic syndromes, systemic juvenile idiopathic arthritis, adult‑onset Still's disease, familial Mediterranean fever, and is studied for reduction of cardiovascular events in patients with atherosclerotic disease.

GNH USA supplies Ilaris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilaris (canakinumab) is used to target the interleukin‑1β mediated inflammatory pathway in several autoinflammatory and systemic inflammatory conditions.

- Cryopyrin‑associated periodic syndromes (CAPS): reduces frequency and severity of fever episodes and systemic inflammation. - Systemic juvenile idiopathic arthritis (SJIA): controls disease activity and improves joint function. - Adult‑onset Still's disease (AOSD): alleviates systemic symptoms and inflammatory markers. - Familial Mediterranean fever (FMF): decreases attack frequency and severity. - Atherosclerotic cardiovascular disease (investigational): may lower risk of major cardiovascular events.

Adverse reactions reported with Ilaris vary from mild to serious and are related to its immunomodulatory activity.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Upper respiratory tract infection: nasopharyngitis or sinusitis. - Headache: mild to moderate intensity. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Serious infections: bacterial, viral, fungal infections requiring medical attention. - Neutropenia: low neutrophil count increasing infection risk. - Allergic reactions: anaphylaxis or severe hypersensitivity. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating Ilaris, clinicians should consider several safety precautions to minimize risk.

- Infection screening: assess for active or latent infections, especially tuberculosis, before treatment. - Immunization status: administer required vaccines prior to therapy; avoid live vaccines during treatment. - Monitoring blood counts: regularly check neutrophil and platelet levels during therapy. - Liver function: evaluate hepatic enzymes before and during treatment. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Canakinumab may interact with other medicines, primarily through additive immunosuppressive effects.

Major Interactions (Avoid): - Live vaccines: concurrent use can cause uncontrolled infection. - Other biologic immunosuppressants: combined therapy may markedly increase infection risk.

Moderate Interactions (Monitor Closely): - Antimicrobial prophylaxis: adjust dosing if used to prevent infections. - CYP450 substrates: generally minimal effect, but monitor drugs with narrow therapeutic index. - Concomitant steroids: may enhance immunosuppression, requiring infection surveillance.